Untreated Hepatocellular Carcinoma in Egypt: Outcome and Prognostic Factors

Overview

Journal J Hepatocell Carcinoma

Date 2016 Aug 11

PMID 27508189

Citations 9

Authors

Ahmed Abdelmabood Zeeneldin

Salem Eid Salem

Amira Diaa Darwish

Mosaad Mahmoud El-Gammal

Marwa Mahmoud Hussein

Mohamed Saadeldin

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is a common cancer worldwide as well as in Egypt with hepatitis C and B, alcohol and aflatoxins being the commonest risk factors.

Aim: The objective of this study was to assess the prognostic factors affecting overall survival (OS) of untreated HCC in Egypt.

Methods: This retrospective study was conducted at Tanta Cancer Center, Egypt where 288 HCC cases who received no specific therapy and were followed-up until death were identified. The impact of possible prognostic factors on OS was assessed using the log-rank test (univariate analyses) and Cox regression method (multivariate analysis).

Results: The median OS of untreated HCC was 2.3 months (95% confidence interval: 1.9-2.6). The 1, 3, 6, 12, 24 months OS rates were 84%, 42%, 21%, 9%, and 3%, respectively. All cases had died by 46 months. Male sex, advanced Child-Pugh class, the clinical presentation of ascites, cough, fatigue, and the presence of metastases were associated with poor survival (P<0.05 for all). In multivariate analysis; cough, presence of ascites, and Child-Pugh class were independent predictors of poor survival.

Conclusion: OS in untreated HCC in Egypt is very short. Many factors interact to produce this dismal survival.

Citing Articles

Local Treatment of Hepatocellular Carcinoma with Oligometastases: A Systematic Review and Meta-Analysis.

Kim S, Lee J, Rim C Cancers (Basel). 2023; 15(13).

PMID: 37444577 PMC: 10340244. DOI: 10.3390/cancers15133467.

Gender disparity and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a 25-year period.

Yue T, Xu M, Cai T, Zhu H, Pourkarim M, De Clercq E Front Public Health. 2022; 10:956712.

PMID: 36091549 PMC: 9459158. DOI: 10.3389/fpubh.2022.956712.

Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis?.

Choe J, Lee H, Rim C World J Gastroenterol. 2022; 28(7):704-714.

PMID: 35317274 PMC: 8891726. DOI: 10.3748/wjg.v28.i7.704.

Molecular Noninvasive Diagnosis of Hepatocellular Carcinoma Using Microsatellite Instability.

Mamdouh S, Aboushousha T, Abdelraouf A, Hamdy H, Seleem M, Hassan H Asian Pac J Cancer Prev. 2021; 22(10):3337-3346.

PMID: 34711011 PMC: 8858233. DOI: 10.31557/APJCP.2021.22.10.3337.

Predictors of 5 year survival rate in hepatocellular carcinoma patients.

Sarveazad A, Agah S, Babahajian A, Amini N, Bahardoust M J Res Med Sci. 2019; 24:86.

PMID: 31741658 PMC: 6856560. DOI: 10.4103/jrms.JRMS_1017_18.

References

Zeeneldin A, Eid Salem S, Tabashy R, Ibrahim A, Alieldin N . Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a single center experience including 221 patients. J Egypt Natl Canc Inst. 2013; 25(3):143-50. DOI: 10.1016/j.jnci.2013.05.003. View

Llovet J, Bustamante J, Castells A, Vilana R, Ayuso M, Sala M . Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1998; 29(1):62-7. DOI: 10.1002/hep.510290145. View

Cabibbo G, Maida M, Genco C, Parisi P, Peralta M, Antonucci M . Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol. 2012; 4(9):256-61. PMC: 3468702. DOI: 10.4254/wjh.v4.i9.256. View

Yip W, Hung H, Lok K, Li K, Li K, Szeto M . Outcome of inoperable hepatocellular carcinoma patients receiving transarterial chemoembolisation: a real-life retrospective analysis in a Hong Kong regional hospital. Hong Kong Med J. 2009; 15(5):339-45. View

Paul S, Gamanagatti S, Sreenivas V, Chandrashekhara S, Mukund A, Gulati M . Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India. Indian J Radiol Imaging. 2011; 21(2):113-20. PMC: 3137848. DOI: 10.4103/0971-3026.82294. View

El-Zayadi A, Badran H, Barakat E, Attia M, Shawky S, Mohamed M . Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005; 11(33):5193-8. PMC: 4320394. DOI: 10.3748/wjg.v11.i33.5193. View

Alberti A, Chemello L, Benvegnu L . Natural history of hepatitis C. J Hepatol. 2000; 31 Suppl 1:17-24. DOI: 10.1016/s0168-8278(99)80369-9. View

Alazawi W, Cunningham M, Dearden J, Foster G . Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010; 32(3):344-55. DOI: 10.1111/j.1365-2036.2010.04370.x. View

Llovet J . Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005; 40(3):225-35. DOI: 10.1007/s00535-005-1566-3. View

10.

Kim U, Doo C, Baek S, Kim J, Lee H, Park S . Natural history and prognostic factors of primary hepatocellular carcinoma: study of 70 untreated patients. Korean J Intern Med. 1989; 4(2):136-41. PMC: 4534990. DOI: 10.3904/kjim.1989.4.2.136. View

11.

FALKSON G, Cnaan A, SCHUTT A, Ryan L, FALKSON H . Prognostic factors for survival in hepatocellular carcinoma. Cancer Res. 1988; 48(24 Pt 1):7314-8. View

12.

Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G . Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol. 2009; 15(15):1843-8. PMC: 2670411. DOI: 10.3748/wjg.15.1843. View

13.

Izzo F, Piccirillo M, Albino V, Palaia R, Belli A, Granata V . Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients. HPB (Oxford). 2013; 15(12):985-90. PMC: 3843617. DOI: 10.1111/hpb.12080. View

14.

El-Zayadi A, Badran H, Shawky S, Emara S, El-Bareedy A, Sobhi M . Effect of surveillance for hepatocellular carcinoma on tumor staging and treatment decisions in Egyptian patients. Hepatol Int. 2010; 4(2):500-6. PMC: 2900559. DOI: 10.1007/s12072-010-9170-x. View

15.

Yeung Y, Lo C, Liu C, Wong B, Fan S, Wong J . Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005; 100(9):1995-2004. DOI: 10.1111/j.1572-0241.2005.00229.x. View

16.

Poustchi H, Sepanlou S, Esmaili S, Mehrabi N, Ansarymoghadam A . Hepatocellular carcinoma in the world and the middle East. Middle East J Dig Dis. 2014; 2(1):31-41. PMC: 4154905. View

17.

Abaza H, Shawky S, Mohamed M, Selim O, Badran H . Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatol Res. 2001; 19(2):170-179. DOI: 10.1016/s1386-6346(00)00105-4. View

18.

Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt Y . Natural history of untreated primary hepatocellular carcinoma: a retrospective study of 157 patients. Am J Clin Oncol. 1998; 21(4):386-91. DOI: 10.1097/00000421-199808000-00014. View

19.

Abdel-Wahab M, Mostafa M, Sabry M, el-Farrash M, Yousef T . Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study. Hepatogastroenterology. 2008; 55(86-87):1754-9. View

20.

Bosch F, Ribes J, Borras J . Epidemiology of primary liver cancer. Semin Liver Dis. 1999; 19(3):271-85. DOI: 10.1055/s-2007-1007117. View